However, despite widespread dysregulation of ANXA2 expression in different cancers, the biological and clinical impact of ANXA2 targeting may considerably vary depending on cellular and tissue specificity, Therefore, a potential clinical application will require individual testing and deep functional and mechanistic characterization for each cancer type. The gene discussed is ANXA2; the disease is cancer.